Cyclosporine

Prodotti simili

Humira

Prezzo da €640.45

Vedi

Eurax Lotion

Prezzo da €5.09

Vedi

Pilex Ointment

Prezzo da €5.09

Vedi

Aquasol A

Prezzo da €12.72

Vedi

Actigall

Prezzo da €86.52

Vedi

Trecator SC

Prezzo da €44.11

Vedi

Let’s be absolutely clear from the start: Cyclosporine is not a dietary supplement. It is a potent, prescription-only immunosuppressive drug. If you are reading this hoping to buy it over the counter or as a “natural” immune booster, stop here. This monograph is for healthcare professionals and deeply informed patients who need to understand a drug that has saved organs but also ruined kidneys.

I’m writing this after twenty years of managing transplant patients and autoimmune cases. I’ve seen cyclosporine pull people back from the brink of rejection. I’ve also seen it destroy renal function in six months when we weren’t careful. This is the real story.

What is Cyclosporine? The Fungal Peptide That Changed Transplantation

Cyclosporine (also spelled cyclosporin, Ciclosporin) is a cyclic undecapeptide—an 11-amino acid ring—isolated from the soil fungus Tolypocladium inflatum (originally Beauveria nivea). It was discovered in 1970 by a Sandoz (now Novartis) scientist who was literally screening soil samples for antifungal agents.

What he found was a compound that killed fungi weakly but suppressed T-cell activation powerfully. The first human trials in 1978 were so dramatic that the entire field of organ transplantation shifted overnight. Before cyclosporine, kidney transplant survival at one year was around 50% with azathioprine and steroids. After cyclosporine? We jumped to 80-90%.

It is classified as a calcineurin inhibitor (CNI) . It is not a cytostatic drug like azathioprine. It does not kill dividing cells. It specifically blocks a single signal pathway in T-lymphocytes. This selectivity is both its genius and its danger.

Key Components and Formulations

The active ingredient is cyclosporine A. But the formulation matters enormously because the drug is highly lipophilic and has terrible oral bioavailability.

• Sandimmune® (original formulation): A crude oil-based emulsion. Bioavailability is 20-30%, highly variable (10-60% depending on bile flow). This variability is a clinical nightmare.
• Neoral® (modified microemulsion): A self-microemulsifying drug delivery system (SMEDDS). Pre-formed microemulsion that forms spontaneously in GI fluids. Bioavailability improves to 30-50%, with much lower variability (CV% drops from 60% to 20%). This is the standard today.
• Gengraf®: Generic equivalent of Neoral.
• IV formulation: Used for initial induction or when GI absorption is impaired. Contains Cremophor EL (polyoxyethylated castor oil)—a vehicle that itself causes anaphylaxis in some patients.
• Topical formulations: Restasis® (ophthalmic emulsion) for dry eye disease. This is the only form available without systemic immunosuppression.

The bioavailability difference between Sandimmune and Neoral is not academic. I had a patient in 2005, a 34-year-old male with a cadaveric kidney, who was stable on Sandimmune for three years. His pharmacy switched him to Neoral without dose adjustment. His trough level went from 180 ng/mL to 450 ng/mL in one week. He developed tremor, hypertension, and a serum creatinine spike from 1.2 to 2.1. We caught it early, but that scenario is why I always specify the formulation.

Mechanism of Action: How Cyclosporine Actually Works

This is where the biochemistry gets beautiful and dangerous.

Cyclosporine enters T-lymphocytes passively. Inside the cell, it binds to cyclophilin A, an intracellular protein that belongs to the immunophilin family. This cyclosporine-cyclophilin complex then binds to and inhibits calcineurin, a calcium/calmodulin-dependent serine/threonine phosphatase.

Why does this matter? Calcineurin is the gatekeeper for T-cell activation. When an antigen-presenting cell engages the T-cell receptor, intracellular calcium rises. This calcium activates calmodulin, which activates calcineurin. Calcineurin then dephosphorylates Nuclear Factor of Activated T-cells (NF-AT) . Dephosphorylated NF-AT translocates to the nucleus and drives transcription of interleukin-2 (IL-2), the master growth factor for T-cells.

Cyclosporine stops this at the calcineurin step. No dephosphorylation. No NF-AT translocation. No IL-2 production. No T-cell proliferation.

But here is the problem: calcineurin is not only in T-cells. It is expressed in many tissues, including:

• Renal tubular cells: Calcineurin is involved in sodium handling and vascular tone. Inhibiting it causes afferent arteriolar vasoconstriction, leading to renal ischemia and fibrosis over time. This is the basis of chronic cyclosporine nephrotoxicity.
• Pancreatic beta-cells: Calcineurin regulates insulin secretion. Inhibition contributes to post-transplant diabetes mellitus.
• Neurons: Calcineurin modulates neurotransmitter release. Inhibition explains the tremor and neurotoxicity.

The drug is selective for T-cells but not specific to them. That distinction is critical.

Pharmacokinetics: The Practical Nightmare

• Absorption: Highly variable, bile-dependent (Sandimmune), improved with Neoral. Food with high fat content increases absorption.
• Distribution: Extensive. Volume of distribution is 4-6 L/kg. Highly protein bound (90% to lipoproteins).
• Metabolism: Extensively via CYP3A4 in the liver and small intestine. This is the root of countless drug interactions.
• Elimination: Primarily biliary. Less than 6% is excreted renally unchanged. Renal impairment does not significantly affect elimination, but nephrotoxicity is still a major issue.

The half-life is variable: 6-27 hours in adults. This is why therapeutic drug monitoring is mandatory.

Indications for Use: What Cyclosporine is Actually Effective For

This list is based on FDA approvals and strong clinical evidence. I have organized it by level of evidence.

#### Solid Organ Transplantation (Highest Evidence)

This is the original indication. Cyclosporine is used for prophylaxis of organ rejection in kidney, liver, heart, lung, and pancreas transplants. It is typically combined with mycophenolate mofetil and corticosteroids. In some protocols, it is used in place of tacrolimus, though tacrolimus has largely replaced cyclosporine as the first-line CNI due to lower rejection rates.

I still use cyclosporine in patients who develop tacrolimus-related neurotoxicity or alopecia. It is not inferior; it is different.

#### Graft-Versus-Host Disease (GVHD) Prophylaxis

For allogeneic hematopoietic stem cell transplant. Cyclosporine is given from day -1 to day 180 post-transplant, often with methotrexate. It reduces the incidence of acute GVHD from approximately 50% to 20-30%.

#### Psoriasis (Severe, Refractory)

FDA-approved for severe, recalcitrant plaque psoriasis in adults. Dose: 2.5-5 mg/kg/day. Response rate is 80-90% within 4-8 weeks. However, it is not a first-line therapy due to nephrotoxicity and hypertension. It is used for short-term control (12-16 weeks) while other agents take effect.

I had a 52-year-old woman with psoriasis covering 60% of her body. Failed methotrexate, failed phototherapy, failed etanercept. Cyclosporine cleared her completely in six weeks. Her creatinine rose from 0.9 to 1.4. We stopped after 12 weeks, switched to a biologic, and her renal function normalized. It was a rescue, not a solution.

#### Rheumatoid Arthritis (Severe, Active)

Approved for treatment of active RA in patients who have not responded to methotrexate alone. Often used in combination with methotrexate. The evidence is weaker than for biologics, but it works.

#### Nephrotic Syndrome (Minimal Change Disease, FSGS)

Used in steroid-resistant or steroid-dependent nephrotic syndrome in children and adults. Dose: 3-5 mg/kg/day. Response rate is 60-80% in minimal change disease, lower in FSGS.

#### Atopic Dermatitis (Severe, Refractory)

Systemic cyclosporine is effective for severe atopic dermatitis in adults and children. Short-term use (8-12 weeks) is common. Topical cyclosporine is not effective due to poor skin penetration.

#### Dry Eye Disease (Topical)

Restasis (0.05% ophthalmic emulsion) is FDA-approved for increasing tear production in patients with dry eye disease due to ocular inflammation. This is the only form that does not require systemic immunosuppression monitoring. It works, but it takes 3-6 months for full effect.

#### Other Off-Label Uses

• Ulcerative colitis: Cyclosporine IV is used as rescue therapy for severe, steroid-refractory UC. Response rate is 80% within 7 days. It avoids colectomy in the short term.
• Pyoderma gangrenosum: Case series show effectiveness.
• Behçet’s disease: Particularly for ocular involvement.
• Alopecia areata: Variable results.

Instructions for Use: Dosing and Monitoring

This is not a drug you prescribe casually. The therapeutic window is narrow, and the consequences of error are severe.

Starting Dose (Oral, Neoral formulation)

Critical rule: Always measure whole blood trough levels (C0) 12 hours after the last dose. Use EDTA blood. Do not use serum or plasma—cyclosporine partitions into red blood cells, and levels will be falsely low.

Dose Adjustments

• Nephrotoxicity: If serum creatinine rises >30% above baseline, reduce dose by 25-50%. If no improvement in 2 weeks, consider switching to another agent.
• Hypertension: Treat with calcium channel blockers (nifedipine, amlodipine). Avoid diltiazem and verapamil—they inhibit CYP3A4 and raise cyclosporine levels.
• Tremor: Dose-dependent. Reduce dose if functional impairment.
• Hepatotoxicity: Reduce dose if transaminases rise >3x ULN.

Drug Interactions: The Landmine Field

Cyclosporine is metabolized by CYP3A4. Anything that induces or inhibits this enzyme will change levels dangerously.

Inhibitors (increase cyclosporine levels, risk of toxicity):

• Ketoconazole, fluconazole, itraconazole
• Erythromycin, clarithromycin
• Diltiazem, verapamil
• Grapefruit juice (avoid completely)
• Amiodarone

Inducers (decrease cyclosporine levels, risk of rejection):

• Rifampin
• Phenytoin, carbamazepine, phenobarbital
• St. John’s Wort (this is a potent inducer; patients must avoid it)
• Efavirenz, nevirapine

Nephrotoxic synergy:

• NSAIDs (any, including COX-2 inhibitors)
• Aminoglycosides (gentamicin, tobramycin)
• Amphotericin B
• Vancomycin
• Foscarnet

I had a patient, a 28-year-old with a kidney transplant, who took ibuprofen for a headache. Three days later, his creatinine went from 1.0 to 3.5. He required dialysis for two weeks. It recovered, but that was a lesson I never forgot.

Contraindications and Side Effects

Absolute Contraindications

• Hypersensitivity to cyclosporine or any excipient (especially Cremophor EL in IV formulation)
• Uncontrolled hypertension
• Uncontrolled infection
• History of malignancy (except non-melanoma skin cancer)
• Severe renal impairment (unless the benefit clearly outweighs risk)

Common Side Effects (Incidence >10%)

• Nephrotoxicity: The big one. Acute (reversible vasoconstriction) and chronic (irreversible interstitial fibrosis). Risk increases with dose, duration, and concurrent nephrotoxic drugs.
• Hypertension: 50-80% of transplant patients develop hypertension within 1 year. Mechanism: sodium retention, vasoconstriction, and direct endothelial damage.
• Tremor: Fine, high-frequency tremor. Dose-dependent. Usually reversible.
• Hirsutism: Increased hair growth, especially on face and arms. This is particularly distressing for women.
• Gingival hyperplasia: Overgrowth of gum tissue. More common in children. Associated with poor oral hygiene and concurrent calcium channel blocker use.
• Hyperlipidemia: Increased LDL and triglycerides.
• Post-transplant diabetes mellitus: 10-20% incidence. Less than tacrolimus but still significant.

Serious Side Effects (Incidence <5%)

• Posterior Reversible Encephalopathy Syndrome (PRES): Headache, visual disturbances, seizures, altered mental status. Requires immediate discontinuation.
• Thrombotic microangiopathy (TMA): Hemolytic uremic syndrome-like picture. Rare but life-threatening.
• Anaphylaxis: With IV formulation (Cremophor EL).
• Increased risk of infections: Including CMV, EBV, BK virus, and Pneumocystis jirovecii.
• Increased risk of malignancy: Lymphoma (especially post-transplant lymphoproliferative disorder, PTLD), skin cancers (squamous cell, basal cell). Risk increases with cumulative immunosuppression.

Clinical Studies and Evidence Base

The landmark study was the Canadian Multicentre Trial (1978-1980), published in The Lancet in 1982. It randomized 50 kidney transplant recipients to cyclosporine plus steroids versus azathioprine plus steroids. One-year graft survival: 86% vs. 50%. This was the turning point.

For psoriasis, the European Multicentre Study (1991) showed that 2.5-5 mg/kg/day produced 80% improvement in PASI scores within 8 weeks. Relapse occurred in 50% of patients within 2 months of discontinuation, confirming that cyclosporine is a suppressive, not curative, therapy.

For nephrotic syndrome, the ISKDC (International Study of Kidney Disease in Children) trial showed that cyclosporine induced remission in 60% of steroid-resistant minimal change disease. However, 40% relapsed within 6 months of stopping.

What the Evidence Does Not Say

Cyclosporine does not improve survival in autoimmune diseases. It improves symptoms and reduces steroid dependence. It does not cure anything. It suppresses inflammation by disabling T-cells. That is the trade-off.

Comparing Cyclosporine with Similar Drugs

Cyclosporine vs. Tacrolimus

Tacrolimus (FK506, Prograf) is also a calcineurin inhibitor but binds to FKBP12 instead of cyclophilin. It is 10-100 times more potent in vitro.

In most transplant centers, tacrolimus is first-line. I use cyclosporine when patients develop tacrolimus-induced alopecia (which is devastating for women) or severe neurotoxicity.

Cyclosporine vs. Mycophenolate Mofetil (MMF)

MMF is an antiproliferative agent that inhibits inosine monophosphate dehydrogenase, blocking purine synthesis in lymphocytes. It is not a CNI. It is often used in combination with cyclosporine or tacrolimus.

• Cyclosporine inhibits T-cell activation (early signal).
• MMF inhibits T- and B-cell proliferation (late signal).

They are synergistic. The combination reduces rejection rates by 30-50% compared to cyclosporine alone.

Choosing a Quality Product

For transplant patients, this is not a choice. You use the brand or generic that your transplant center is comfortable with. Switching between formulations (Sandimmune to Neoral, or brand to generic) requires careful monitoring.

For dermatologic or rheumatologic use, the Neoral formulation is preferred due to more predictable absorption. Generic Neoral (Gengraf, various) is acceptable if the patient is stable and levels are monitored.

What to Look For

• Formulation: Microemulsion (Neoral-type) is always preferred over oil-based (Sandimmune).
• Capsule strength: 25 mg, 50 mg, 100 mg.
• Oral solution: 100 mg/mL. Useful for dose titration in children.
• Expiration: Cyclosporine is stable at room temperature. Do not refrigerate the oral solution—it can precipitate.

Frequently Asked Questions (FAQ)

Can cyclosporine be taken with food?

Yes, but be consistent. High-fat meals increase absorption. Take it at the same time each day with the same meal.

What is the most important monitoring parameter?

Serum creatinine. Check it weekly for the first month, then monthly. A 30% rise is a red flag.

Can I drink grapefruit juice while taking cyclosporine?

No. Grapefruit juice inhibits CYP3A4 in the gut, increasing cyclosporine levels by 50-100%. This can cause acute nephrotoxicity.

Is cyclosporine safe during pregnancy?

It is pregnancy category C. Animal studies show teratogenicity at high doses, but human data are limited. It is used in pregnant transplant recipients when the benefit of preventing rejection outweighs the risk. The risk of fetal growth restriction and prematurity is increased.

How long can I take cyclosporine for psoriasis?

FDA labeling recommends intermittent short-term therapy (12-16 weeks). Continuous therapy beyond 1 year is associated with irreversible nephrotoxicity. If you need continuous therapy, consider transitioning to a biologic.

What should I do if I miss a dose?

Take it as soon as you remember, unless it is within 4 hours of the next dose. In that case, skip the missed dose. Do not double up.

Conclusion: The Clinical Reality

Cyclosporine is a tool, not a solution. It is one of the most effective immunosuppressants we have, but its toxicity profile demands respect. I have used it in hundreds of patients. I have seen it save kidneys, livers, and hearts. I have also seen it destroy renal function in patients who were not monitored closely.

The key is vigilance. Check creatinine. Check trough levels. Monitor blood pressure. Watch for infections. Do not use it for long-term control of autoimmune diseases unless you have no other option.

Final recommendation: If you are a clinician, use cyclosporine when the indication is clear and the monitoring is in place. If you are a patient, do not take this drug without a physician who understands its risks. It is not a supplement. It is a powerful medicine that demands respect.

Disclaimer: This monograph is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any medication regimen.